

**Multiple Myeloma Canada /  
Myélome Multiple Canada  
Financial Statements  
For the year ended December 31, 2018**

**Multiple Myeloma Canada / Myélome Multiple Canada**  
**Financial Statements**  
**For the year ended December 31, 2018**

---

**Contents**

<b>Independent Auditor's Report</b>	3 - 5
<b>Financial Statements</b>	
Statement of Financial Position	6
Statement of Changes in Net Assets	7
Statement of Revenue and Expenditures	8
Statement of Cash Flows	9
Notes to Financial Statements	10 - 16
<b>Supplementary Financial Information</b>	
Schedule of General and Administrative Expenses	17



Tel: 514-931-0841  
Fax: 514-931-9491  
www.bdo.ca

BDO Canada s.r.l./S.E.N.C.R.L./LLP  
1000 De La Gauchetière Street West  
Suite 200  
Montréal, Québec H3B 4W5

---

## Independent Auditor's Report

---

To the board of directors of  
Multiple Myeloma Canada / Myélome Multiple Canada

### Qualified Opinion

We have audited the financial statements of Multiple Myeloma Canada / Myélome Multiple Canada, which comprise the statement of financial position as at December 31, 2018, and the statements of revenue and expenditures, changes in net assets and cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies.

In our opinion, except for the effects of the matter described in the Basis for Qualified Opinion section of our report, the accompanying financial statements present fairly, in all material respects, the financial position of Multiple Myeloma Canada / Myélome Multiple Canada as at December 31, 2018, and its financial performance and its cash flows for the year then ended in accordance with Canadian accounting standards for not-for-profit organizations.

### Basis for Qualified Opinion

We conducted our audit in accordance with Canadian generally accepted auditing standards. Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Statements* section of our report. We are independent of the Entity in accordance with the ethical requirements that are relevant to our audit of the financial statements in Canada, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our qualified opinion.

In common with many charitable organizations, the entity derives revenue from donations and cash receipts the completeness of which is not susceptible to satisfactory audit verification. Accordingly, our audit of these revenues was limited to the amounts recorded in the records of the organization and we were not able to determine whether any adjustments might be necessary to revenues other than grants and investment income, excess (deficiency) of revenue over expenditures, and cash flows for the years ended December 31, 2018 and December 31, 2017 assets and net assets as at December 31, 2018 and December 31, 2017.

---

## Independent Auditor's Report

---

### **Responsibilities of Management and Those Charged with Governance for the Financial Statements**

Management is responsible for the preparation and fair presentation of these financial statements in accordance with Canadian accounting standards for not-for-profit organizations, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Entity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Entity or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Entity's financial reporting process.

### **Auditor's Responsibilities for the Audit of the Financial Statements**

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Canadian generally accepted auditing standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with Canadian generally accepted auditing standards, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

---

## Independent Auditor's Report

---

- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Entity's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Entity's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Entity to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

*BDO Canada* s.r.l./S.E.N.C.R.L./LLP<sup>1</sup>

Montréal, Québec  
June 7, 2019

---

<sup>1</sup> CPA auditor, CA, public accountancy permit No. A122867



---

## Multiple Myeloma Canada / Myélome Multiple Canada Statement of Changes in Net Assets

For the year ended December 31	2018	2017
Unrestricted net assets, beginning of the year	\$ 2,609,700	\$ 2,326,896
(Deficiency) excess of revenues over expenses for the year	<u>(52,019)</u>	<u>282,804</u>
Unrestricted net assets, end of the year	<u>\$ 2,557,681</u>	<u>\$ 2,609,700</u>

The accompanying notes are an integral part of these financial statements.

## Multiple Myeloma Canada / Myélome Multiple Canada Statement of Revenue and Expenditures

For the year ended December 31	2018	2017
<b>Revenue</b>		
Industry grants	\$ 1,134,500	\$ 956,168
Fundraising events	679,462	655,525
Other contributions	363,712	176,979
Other revenue	43,379	53,659
Investment income	29,476	46,273
Unrealized foreign exchange gain (loss)	20,601	(30,011)
	<u>2,271,130</u>	<u>1,858,593</u>
<b>Expenditures</b>		
Science and research	819,226	488,254
Patient and education programs	478,825	292,983
General and administration (Schedule)	211,241	187,882
Access and advocacy	160,142	165,733
Fundraising	212,414	167,883
Awareness and communication	298,381	200,377
Governance	88,029	59,507
Unrealized loss on investments at fair value	50,124	54,217
Realized loss (gain) on disposal of investments	4,767	(41,047)
	<u>2,323,149</u>	<u>1,575,789</u>
<b>(Deficiency) excess of revenues over expenditures for the year</b>	<b>\$ (52,019)</b>	<b>\$ 282,804</b>

The accompanying notes are an integral part of these financial statements.



## Multiple Myeloma Canada / Myélome Multiple Canada Statement of Cash Flows

For the year ended December 31	2018	2017
<b>Cash flows from operating activities</b>		
(Deficiency) excess of revenue over expenditures for the year	\$ (52,019)	\$ 282,804
Items not affecting cash		
Realized loss (gain) on disposal of investments	4,767	(41,047)
Unrealized loss on investments at fair value	50,124	54,217
Amortization of capital assets	6,405	3,014
Amortization of intangible asset	23,536	5,468
	<u>32,813</u>	<u>304,456</u>
Changes in non-cash working capital balances		
Prepaid expenses	927	(8,257)
Contributions receivable	164,020	(114,768)
Sales taxes receivable	(6,704)	67,640
Accounts payable and accrued liabilities	(54,447)	(91,232)
Deferred contributions	(155,000)	155,000
	<u>(18,391)</u>	<u>312,839</u>
<b>Cash flows from investing activities</b>		
Purchase of investments	(546,374)	(1,922,936)
Proceeds on disposal of investments	517,768	1,439,663
Purchase of capital assets	(6,874)	(25,784)
Purchase of intangible asset	(86,536)	(32,809)
	<u>(122,016)</u>	<u>(541,866)</u>
<b>Net decrease in cash and cash equivalents during the year</b>	<b>(140,407)</b>	<b>(229,027)</b>
<b>Cash and cash equivalents, beginning of the year</b>	<b>1,837,048</b>	<b>2,066,075</b>
<b>Cash and cash equivalents, end of the year</b>	<b>\$ 1,696,641</b>	<b>\$ 1,837,048</b>

The accompanying notes are an integral part of these financial statements.

---

# Multiple Myeloma Canada / Myélome Multiple Canada

## Notes to Financial Statements

December 31, 2018

---

### 1. Significant Accounting Policies

**Purpose of Organization** Multiple Myeloma Canada / Myélome Multiple Canada is incorporated under the *Canada Corporations Act* as a not-for-profit organization and is a registered charity under paragraph 149 (1) (f) of the *Income Tax Act*. Multiple Myeloma Canada / Myélome Multiple Canada is the only national organization exclusively devoted to the Canadian myeloma community. As a patient-driven, patient-focused organization, Multiple Myeloma Canada / Myélome Multiple Canada works with leading myeloma researchers and clinicians as well as other cancer organizations and local support groups across Canada, strengthening the voice of the Canadian myeloma community and improving the quality of life of myeloma patients, their caregivers and families through education, awareness, advocacy and research.

**Basis of Accounting** The financial statements have been prepared using Canadian accounting standards for not-for-profit organizations.

**Revenue Recognition** The Organization follows the deferral method of accounting for contributions. Restricted contributions are recognized as revenue in the year in which the related expenses are incurred. Unrestricted contributions, if any, industry grants, fundraising and other revenue are recognized as revenue when received or receivable if the amount to be received can be reasonably estimated and collection is reasonably assured.

Investments income is recognized when earned.

**Contributed Services** In the course of its activities, the Organization uses the services of volunteers as well as services and materials provided without monetary compensation. Given that the Organization does not pay for these services or materials and that it is impractical to estimate their fair value, they are not recognized in the financial statements.

**Capital Assets** Capital assets are stated at cost less accumulated amortization. Amortization based on the estimated useful lives of the assets is provided at the following annual rates:

	<b>Method</b>	<b>Rate</b>
Computer equipment	Declining balance	3 years
Furniture and fixtures	Declining balance	5 years
Building improvements	Straight-line	10 years

---

## Multiple Myeloma Canada / Myélome Multiple Canada Notes to Financial Statements

December 31, 2018

---

### 1. Significant Accounting Policies (continued)

**Intangible Asset**                      Intangible asset is stated at cost less accumulated amortization. Amortization based on the estimated useful life of the asset is provided at the following annual rate:

	Method	Rate
Software	Declining balance	3 years

**Cash and Cash Equivalents**                      The policy of the Organization is to disclose bank balances under cash and cash equivalents, including bank overdrafts with balances that fluctuate frequently from being positive to overdrawn, and temporary investments with a maturity of three months or less from the date of acquisition.

**Foreign Currency Translation**                      Foreign currency accounts are translated into Canadian dollars as follows:

At the transaction date, each asset, liability, revenue and expense is translated into Canadian dollars by the use of the exchange rate in effect at that date. At the year-end date, monetary assets and liabilities are translated into Canadian dollars by using the exchange rate in effect at that date. The resulting foreign exchange gains and losses are included in income in the current period.

**Financial Instruments**                      The Organization's financial instruments consist of cash and cash equivalents, contributions receivable, investments and accounts payable.

*Measurement of Financial Instruments*

The Organization initially measures its financial assets and liabilities at fair value. The Organization subsequently measures all its financial assets and liabilities at amortized cost with the exception of investments quoted in an active market which are subsequently measured at fair value based on closing market prices.

Financial assets measured at amortized cost include cash, and contributions receivable.

Financial assets measured at fair value include investments.

Financial liabilities measured at amortized cost include accounts payable.

---

## Multiple Myeloma Canada / Myélome Multiple Canada Notes to Financial Statements

December 31, 2018

---

### 1. Significant Accounting Policies (continued)

**Financial Instruments  
(continued)**

*Impairment*

Financial assets measured at amortized cost are tested for impairment when there are indicators of impairment. The amount of the write-down is recognized in excess of revenue over expenditures. The previously recognized impairment loss may be reversed to the extent of the improvement, directly or by adjusting the allowance account, provided it is not greater than the amount that would have been reported at the date of reversal had the impairment not been recognized previously. The amount of the reversal is recognized in excess of revenue over expenditures.

**Allocation of Expenses**

The Organization engages in various programs related to their purpose as set out above. The cost of each program includes the costs of personnel that are directly related to providing these programs. The allocation is based on the time devoted to each program.

---

---

## Multiple Myeloma Canada / Myélome Multiple Canada Notes to Financial Statements

December 31, 2018

---

### 2. Investments

The carrying amounts of investments are comprised of the following:

	2018	2017
Marketable securities at cost	\$ 1,004,682	\$ 980,843
Changes in fair value	(52,812)	(2,688)
Fair value	\$ 951,870	\$ 978,155

---

### 3. Capital Assets

	2018		2017	
	Cost	Accumulated Amortization	Cost	Accumulated Amortization
Computer equipment	\$ 15,665	\$ (5,053)	\$ 8,791	\$ (1,465)
Furniture and fixtures	13,975	(3,913)	13,975	(1,398)
Building improvements	3,018	(453)	3,018	(151)
	32,658	(9,419)	25,784	(3,014)
Net book value		\$ 23,239		\$ 22,770

---

### 4. Intangible Asset

	2018		2017	
	Cost	Accumulated Amortization	Cost	Accumulated Amortization
Software	\$ 119,346	\$ (29,005)	\$ 32,809	\$ (5,468)
Net book value		\$ 90,341		\$ 27,341

---

---

## Multiple Myeloma Canada / Myélome Multiple Canada Notes to Financial Statements

December 31, 2018

---

### 5. Accounts Payable and Accrued Liabilities

	2018	2017
Accounts payable	\$ 149,651	\$ 82,196
Accrued liabilities	7,843	21,360
Salaries and vacation payable	26,174	12,446
Government remittances	14,831	9,944
Contribution payable to research program	100,000	227,000
	\$ 298,499	\$ 352,946

---

### 6. Deferred Contributions

The following summarizes the changes in deferred contributions related to projects carried out in the current year:

	2018	2017
Balance, beginning of year	\$ 155,000	\$ -
Deferred contributions received during the year	-	155,000
Less: amount recognized in revenue in the year	(155,000)	-
	\$ -	\$ 155,000

---

### 7. Commitments

The Organization has entered into a real estate lease agreement for its premises and office equipment until March 2027 with future minimum lease payments as follows:

2019	\$	16,898
2020		16,898
2021		16,898
2022		19,094
2023		19,917
Thereafter		76,460
	\$	166,165

---

---

## Multiple Myeloma Canada / Myélome Multiple Canada Notes to Financial Statements

December 31, 2018

---

### 8. Risks Arising from Financial Instruments

The Organization is exposed to various risks by virtue of holding financial instruments. There have been no changes to the Organization's exposure to those risks nor in how those risks are managed since the previous year.

#### Currency risk

Currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign exchange rates.

The Organization is exposed to currency risk in foreign currency rates resulting from U.S. dollar cash and cash equivalents and investments. At December 31, 2018, cash denominated in U.S. dollars expressed in Canadian dollars totaled \$43,573 (2017 - \$543,820) and investments denominated in U.S. dollars expressed in Canadian dollars totaled \$Nil (2017 - \$166,478).

#### Credit risk

Credit risk is the risk that one party to a financial instrument will cause a financial loss for the other party by failing to discharge an obligation. The Organization is exposed to credit risk with respect to cash and cash equivalents and investments from the potential default by counterparties that carry the Organization's cash and cash equivalents and investments. The Organization mitigates the credit risk by dealing with only large financial institutions with good credit ratings. The Organization is also exposed to credit risk arising from its contributions receivable. The Organization works to ensure that the receivables meet all eligibility criteria in order to qualify to receive the funding.

The Organization has a concentration of credit risk with respect to contributions receivable from one organization. As at December 31, 2018, four contributors accounted for 85% of all contributions receivable (2017 - four contributors accounted for 93%).

#### Liquidity risk

Liquidity risk is the risk that an entity will encounter difficulty in meeting obligations associated with financial liabilities. The Organization is subject to liquidity risk on its accounts payable which arise from its daily operations. The Organization manages this risk by monitoring working capital and cash flows needs.

#### Other price risk

Other price risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market prices (other than those arising from interest rate risk or currency risk), whether those changes are caused by factors specific to the individual financial instrument or its issuer, or factors affecting all similar financial instruments traded in the market. The Organization is exposed to price risk from its investment portfolio. The Organization moderates this risk through the selection and diversification of securities held within the portfolio.

---

---

## Multiple Myeloma Canada / Myélome Multiple Canada Notes to Financial Statements

December 31, 2018

---

### 9. Comparative Figures

Certain comparative figures have been reclassified to conform with the current year's presentation.

---



---

**Multiple Myeloma Canada / Myélome Multiple Canada**  
**Schedule of General and Administrative Expenses**

<b>For the year ended December 31</b>	<b>2018</b>	<b>2017</b>
Salaries	\$ 85,620	\$ 66,336
Rent	47,035	35,310
Professional services	18,335	23,963
Accounting and legal	8,479	20,982
License and memberships	13,540	10,050
Stationery, postage and telephone	14,213	11,821
Insurance	9,460	4,459
Bank and credit card fees	6,342	4,038
Amortization of capital Assets	4,907	3,123
Repairs and Maintenance	2,032	2,897
Traveling	1,278	1,145
Office relocation	-	3,758
	<hr/>	<hr/>
	<b>\$ 211,241</b>	<b>\$ 187,882</b>

---